SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

Statin Medication: Scoping Review with ☸️SAIMSARA.

Longevity icon

Longevity & Public Health

Issue 2, Volume 1, 2026

DOI: 10.62487/saimsarad97359b1

Editorial note
• Last update: 2026-04-27 08:56:58
What is this paper about
Statins are not just cholesterol drugs: across an enormous evidence base, this review shows how they may help protect healthspan and longevity by lowering recurrent vascular events and mortality, while also exposing the real trade-offs around diabetes risk, intolerance, and poor long-term adherence. The full paper is worth reading because it separates where statins most clearly extend durable cardiovascular protection from where the evidence becomes mixed, controversial, and potentially relevant to broader aging-related pathways such as inflammation, liver disease, and neurocognitive decline.
Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.


Abstract: The aim of this scoping review is to synthesize multi-disciplinary evidence regarding the clinical outcomes, safety profiles, and determinants of adherence associated with statin medication across diverse global populations and clinical settings. The review utilises 1637 original studies with 43987683 total participants (topic deduplicated ΣN). The evidence map suggests that statin medication remains strongly associated with lower mortality and recurrent vascular events across major cardiovascular settings, with reported hazard ratios for mortality ranging from 0.38 after ischemic stroke to 0.71 in primary prevention populations. At the same time, the mapped literature highlights a consistent safety and implementation tension: new-onset diabetes and glycemic progression were repeatedly associated with statin exposure, with odds ratios up to 1.48 in postmenopausal women and a 46% increased risk reported in middle-aged men, while roughly half of patients showed suboptimal persistence within the first year. Beyond lipid lowering, the evidence supports broader anti-inflammatory, perioperative, hepatology, and selected oncology signals, but these noncardiovascular benefits were more heterogeneous and were often derived from observational or mechanistic studies rather than definitive trials. Clinically, the findings support continued emphasis on maintaining statin therapy in appropriate high-risk patients while proactively addressing adherence barriers, intolerance concerns, cost, and glycemic monitoring. Future research should prioritize better-controlled prospective studies and pragmatic trials that clarify heterogeneity in diabetes risk, muscle symptoms, neurologic associations, and potential repurposing benefits in cancer and liver disease.

Keywords: Statin; Statin medication adherence; Diabetes progression; Cardiovascular outcomes; Cancer survival; Medication discontinuation; Insulin resistance; Poststroke depression; Quality of life; Bone mineral density; Dose-response relationship; Cholesterol;

Review Stats

Get access to the full paper

Unlock the full evidence map

The full evidence review, including the Introduction, Methods, Results, Discussion, Conclusion, figures, and complete reference index, opens after purchase or sign-in. The Evidence Object JSON is a separate machine-readable evidence product: a concentrated synthesis of results, topic-level evidence, and discussion across original and non-original studies. It can be directly input into your LLM, agent, or RAG workflow.

Reference Index (344)